MB, Levis & Associates’s AstraZeneca AZN Stock Holding History

MB, Levis & Associates’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$120K	Hold	745	–	–	0.04%	74
2026 Q2	$141K	Buy	+745	New	+$140K	0.05%	71
2026 Q1	–	Sell	-745	Closed	-$137K	–	235
2025 Q4	$137K	Hold	745	–	–	0.06%	67
2025 Q3	$114K	Buy	745 +4	+0.5%	+$605	0.05%	75
2025 Q2	$103K	Hold	741	–	–	0.05%	86
2025 Q1	$109K	Buy	741 +11	+2%	+$1.59K	0.05%	82
2024 Q4	$95.7K	Hold	730	–	–	0.05%	88
2024 Q3	$114K	Buy	730 +4	+0.6%	+$646	0.06%	78
2024 Q2	$113K	Hold	726	–	–	0.06%	78
2024 Q1	$98.3K	Buy	726 +11	+2%	+$1.46K	0.05%	86
2023 Q4	$96.3K	Hold	715	–	–	0.06%	83
2023 Q3	$96.8K	Buy	715 +5	+0.7%	+$683	0.06%	81
2023 Q2	$102K	Hold	710	–	–	0.07%	81
2023 Q1	$98.6K	Buy	710 +10	+1%	+$1.34K	0.07%	80
2022 Q4	$94.9K	Buy	+700	New	+$87.8K	0.07%	76

Other funds holding AZN

Amundi Paris, France $496B AUM 35.36% 1-Year Est. Return

Fisher Asset Management Camas, Washington $348B AUM 26.9% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Sanders Capital West Palm Beach, Florida $103B AUM 36.66% 1-Year Est. Return

SEB Asset Management Stockholm $27B AUM

LBP AM Paris, France $11.2B AUM 34.48% 1-Year Est. Return

M&G plc London, United Kingdom $19.9B AUM 15.09% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

MB, Levis & Associates's AZN Position: Q3 2026 in Review

MB, Levis & Associates held its AstraZeneca (AZN) position steady in Q3 2026 at 745 shares worth $120K. The position accounts for 0.04% of the portfolio, ranked #74.

MB, Levis & Associates first reported a position in AZN in Q4 2022 and has held it in 15 quarters since. The position peaked at $141K in Q2 2026. 782 funds tracked by Wall St. Rank hold AZN as of Q3 2026.

MB, Levis & Associates held 745 shares of AstraZeneca worth $120K as of Q3 2026.
MB, Levis & Associates left its AstraZeneca share count unchanged in Q3 2026.
AstraZeneca made up 0.04% of MB, Levis & Associates's portfolio in Q3 2026, its #74 holding.
MB, Levis & Associates first reported a position in AstraZeneca in Q4 2022 and has held it in 15 quarters since.
MB, Levis & Associates's AstraZeneca position peaked at $141K in Q2 2026.
782 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2026.

Based on MB, Levis & Associates's 13F filing for Q3 2026, filed 16 Oct 2026.